Inflammatory Breast Cancer News and Research

RSS

Inflammatory breast cancer is a form of breast cancer that leads to inflammation and swelling of the lymphatic channels of the breast. Rather than forming a lump, cancer cells grow along the inside of the lymph vessels in the breast skin and obstruct them.

Two new research papers reveal how breast cancer cells avoid anoikis

Two new papers from the lab of Zach Schafer, Coleman Assistant Professor of Cancer Biology at the University of Notre Dame, offer insights into how breast cancer cells avoid anoikis, which is cell death induced by detachment from the extracellular matrix (ECM).

21 Apr 2015

Researchers devise new technique to deliver cancer treatment

A team of researchers has devised a new way to target tumors with cancer-fighting drugs, a discovery that may lead to clinical treatments for cancer patients.

5 Feb 2015

Two new drug compounds appear to be effective in treating endometriosis

Two new drug compounds - one of which has already proven useful in a mouse model of multiple sclerosis - appear to be effective in treating endometriosis, a disorder that, like MS, is driven by estrogen and inflammation, scientists report in Science Translational Medicine.

22 Jan 2015

CTCs in blood of metastatic cancer patients give genomic read-out of breast cancer

The genetic fingerprint of a metastatic cancer is constantly changing, which means that the therapy that may have stopped a patient's cancer growth today, won't necessarily work tomorrow.

9 Oct 2014

New mechanism of chemotherapy resistance in triple-negative inflammatory breast cancer

Researchers at Roswell Park Cancer Institute (RPCI) have identified a mechanism of breast cancer cells that leads to chemotherapy resistance in inflammatory breast cancer.

8 Jul 2014

BPA appears to increase proliferation of breast cancer cells, diminish effectiveness of treatments

Bisphenol A (BPA), a chemical commonly used in plastics, appears to increase the proliferation of breast cancer cells, according to Duke Medicine researchers presenting at an annual meeting of endocrine scientists.

23 Jun 2014

Romidepsin drug shows surprising benefit in preclinical studies of inflammatory breast cancer

A drug now used to treat a type of lymphoma has shown surprising benefit in preclinical studies of inflammatory breast cancer, according to a researcher at Thomas Jefferson University's Kimmel Cancer Center.

11 Dec 2013

Sanofi US launches second PiPH innovation challenge to improve drug development process

Today, Sanofi US launched its second Partners in Patient Health Innovation Challenge: Collaborate | Innovate, which will award $100,000 to the winning team. This year's theme is "Co-Creating for Breakthroughs: Moving toward a collaborative research and development ecosystem."

10 Dec 2013

Researchers reveal why some breast cancer cells are resistant to chemotherapy

Researchers at the UNC School of Medicine, working with cell lines in a lab, have discovered why some of the most aggressive and fatal breast cancer cells are resistant to chemotherapy, and UNC scientists are developing ways to overcome such resistance.

26 Nov 2013

Nearly 2/3 of solid tumors carry at least one mutation that may be targeted by existing compound

Nearly two-thirds of solid tumors carry at least one mutation that may be targeted, or medicated, by an existing compound, according to new findings from researchers Fox Chase Cancer Center that will be presented at the 49th Annual Meeting of the American Society of Clinical Oncology on June 3.

1 Jun 2013

Novel drug seems to increase effectiveness of usual chemotherapy against IBC

Researchers in the University of Delaware's Department of Biological Sciences are investigating a new drug that has shown positive results in early tests of its ability to fight a rare and aggressive form of breast cancer.

8 Mar 2013

Quantum dots can rapidly deliver calcitriol to targeted tumor sites for treatment of IBC

The shortened daylight of a Maine winter may make for long, dark nights - but it has shone a light on a novel experimental approach to fighting inflammatory breast cancer (IBC), an especially deadly form of breast cancer.

2 Feb 2013

Biophysical Society Annual Meeting to highlight innovations in medicine, physics, and more

Honeybee silk-inspired materials; a deconstruction of the Ebola virus; how microbes evolve resistance to antibiotics; and a possible connection between Alzheimer's disease and type II diabetes are just some of the intriguing topics that will be presented at the 57th Annual Meeting of the Biophysical Society (BPS).

22 Jan 2013

18F-FDG PET/CT may become important distant staging modality in patients with breast cancer

New research published in the January issue of The Journal of Nuclear Medicine shows that 18F-fludeoxyglucose (18F-FDG) positron emission tomography (PET)/computed tomography (CT) imaging offers significant prognostic stratification information at initial staging for patients with locally advanced breast cancer. When compared to conventional imaging, 18F-FDG PET/CT more accurately showed lesions in the chest, abdomen and bones in a single session, changing management for more than 50 percent of the patients in the study.

3 Jan 2013

New 3D culture system mimics environment surrounding inflammatory breast cancer cells

Inflammatory breast cancer (IBC) is a very rare and aggressive disease that progresses rapidly and is associated with a very low survival rate. To understand how this type of cancer spreads, it's crucial to characterize the interactions between cancer cells and their 3D environment.

10 Dec 2012

Statins improves progression-free survival in patients with inflammatory breast cancer

Researchers from The University of Texas MD Anderson Cancer Center found statins, the commonly used drug to lower cholesterol, improved progression-free survival in patients with inflammatory breast cancer (IBC).

6 Dec 2012

Bio-Path to initiate BP-100-1.01 Phase I trial for treatment of two types of breast cancer

Bio-Path Holdings, Inc., a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, today announced it is initiating development of its lead cancer drug BP-100-1.01 (Liposomal Grb-2) to treat triple negative breast cancer (TNBC) and inflammatory breast cancer (IBC), two cancers characterized by formation of aggressive tumors and relatively high mortality rates.

6 Dec 2012

Tumor count in the breast an important consideration for providing radiation therapy

Not all women diagnosed with operable breast cancer present with a single tumor; some have multifocal disease appear in the breast, which means multiple tumors found in the same breast quadrant, while others have multicentric disease, where multiple tumors are found in separate breast quadrants. Multifocal or multicentric disease is not a standard indication to receive radiation after mastectomy. For patients who undergo lumpectomy, radiation dose and extent is not altered based on multifocal or multicentric disease compared to patients presenting with a single tumor.

29 Oct 2012

Ampio announces advancement of NCE001 to preclinical development

Ampio Pharmaceuticals, Inc., a biopharmaceutical company developing repurposed drugs and new molecular entities (NMEs) that treat inflammatory diseases, including osteoarthritis, diabetic macular edema (DME) and sexual dysfunction and conducting clinical trials on its four lead drugs announced today the advancement of NCE001, from its proprietary methylphenidate derivatives family of compounds, to preclinical development for the treatment of glioblastoma multiforme, renal cell carcinoma and inflammatory breast cancer following the granting of multiple composition of matter and use patents in the USA, Canada, Europe and China.

17 Jul 2012

Lapatinib-pazopanib combination therapy not beneficial for patients with inflammatory breast cancer

Inflammatory breast cancer is a very aggressive type of cancer associated with early metastasis and poor survival rates, and the prognosis is even worse for patients with tumors expressing the ErbB2 receptor. The ErbB2-inhibiting drug lapatinib can slow the spread of cancer cells in individuals with advanced breast cancer who have already tried other chemotherapy medications.

2 Jun 2012